trending Market Intelligence /marketintelligence/en/news-insights/trending/FM4pg3DyhRoGQVI_3ure4w2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Venn Life Sciences unit goes public

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Venn Life Sciences unit goes public

Venn Life Sciences Holdings PLC unit Integumen PLC went public on the AIM market of the London Stock Exchange, raising £2.3 million in an equity placement.

Venn Life owned 41.51% of the Ireland-based personal healthcare company and now owns 25.59% of the unit following admission to the market.

Venn Life is participating in the IPO and subscribed for 8 million new shares of Integumen for a total cash consideration of £400,000. Based on the placing price of 5 pence per share, Integumen has a market capitalization of about £8.3 million.

As part of the IPO, Paul Kennedy has retired from the Venn board and become a director of Integumen.